Oren Livnat
Stock Analyst at HC Wainwright & Co.
(3.65)
# 752
Out of 5,169 analysts
124
Total ratings
54.62%
Success rate
23.22%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Oren Livnat
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCRX Pacira BioSciences | Maintains: Buy | $48 → $65 | $22.02 | +195.19% | 20 | Apr 8, 2025 | |
| VRCA Verrica Pharmaceuticals | Reiterates: Neutral | n/a | $5.71 | - | 12 | Apr 8, 2025 | |
| COLL Collegium Pharmaceutical | Reiterates: Buy | $50 | $34.80 | +43.68% | 10 | Mar 24, 2025 | |
| TRVI Trevi Therapeutics | Reiterates: Buy | $13 | $10.69 | +16.93% | 7 | Mar 19, 2025 | |
| ANIP ANI Pharmaceuticals | Reiterates: Buy | $94 | $74.17 | +26.74% | 13 | Mar 17, 2025 | |
| ZVRA Zevra Therapeutics | Reiterates: Buy | $20 | $9.55 | +109.42% | 9 | Mar 13, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $200 → $217 | $180.45 | +20.25% | 17 | Mar 10, 2025 | |
| XERS Xeris Biopharma Holdings | Reiterates: Buy | $6.6 → $8 | $5.43 | +47.33% | 11 | Mar 7, 2025 | |
| TARS Tarsus Pharmaceuticals | Reiterates: Buy | $73 | $68.24 | +6.98% | 9 | Feb 26, 2025 | |
| GRCE Grace Therapeutics | Reiterates: Buy | $12 | $4.44 | +170.27% | 1 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7.5 | $2.61 | +187.36% | 6 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $8 | $0.90 | +789.09% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $60 | $7.30 | +715.07% | 5 | Aug 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $252 → $198 | $0.58 | +33,763.52% | 2 | May 7, 2021 |
Pacira BioSciences
Apr 8, 2025
Maintains: Buy
Price Target: $48 → $65
Current: $22.02
Upside: +195.19%
Verrica Pharmaceuticals
Apr 8, 2025
Reiterates: Neutral
Price Target: n/a
Current: $5.71
Upside: -
Collegium Pharmaceutical
Mar 24, 2025
Reiterates: Buy
Price Target: $50
Current: $34.80
Upside: +43.68%
Trevi Therapeutics
Mar 19, 2025
Reiterates: Buy
Price Target: $13
Current: $10.69
Upside: +16.93%
ANI Pharmaceuticals
Mar 17, 2025
Reiterates: Buy
Price Target: $94
Current: $74.17
Upside: +26.74%
Zevra Therapeutics
Mar 13, 2025
Reiterates: Buy
Price Target: $20
Current: $9.55
Upside: +109.42%
Jazz Pharmaceuticals
Mar 10, 2025
Maintains: Buy
Price Target: $200 → $217
Current: $180.45
Upside: +20.25%
Xeris Biopharma Holdings
Mar 7, 2025
Reiterates: Buy
Price Target: $6.6 → $8
Current: $5.43
Upside: +47.33%
Tarsus Pharmaceuticals
Feb 26, 2025
Reiterates: Buy
Price Target: $73
Current: $68.24
Upside: +6.98%
Grace Therapeutics
Feb 18, 2025
Reiterates: Buy
Price Target: $12
Current: $4.44
Upside: +170.27%
Jan 4, 2024
Reiterates: Buy
Price Target: $7.5
Current: $2.61
Upside: +187.36%
May 13, 2022
Maintains: Buy
Price Target: $14 → $8
Current: $0.90
Upside: +789.09%
Aug 26, 2021
Maintains: Buy
Price Target: $43 → $60
Current: $7.30
Upside: +715.07%
May 7, 2021
Maintains: Buy
Price Target: $252 → $198
Current: $0.58
Upside: +33,763.52%